Aptamer therapeutics advance

/Home/Biologics Delivery - Protein Synthesis/Aptamers - Protein Synthesis

Aptamer therapeutics advance
Available online 18 April 2006.
Jennifer F Lee, Gwendolyn M Stovall and Andrew D Ellington
Current Opinion in Chemical Biology
Aptamers are selected nucleic acid binding species with affinities and specificities for protein targets that rival those of monoclonal antibodies. Furthermore, aptamers have definite advantages over antibodies, in that they can be chemically synthesized and modifications can be introduced that improve their stabilities and pharmacokinetic properties. A number of aptamers against therapeutically important targets have shown efficacy in cell and animal models, and a handful of aptamers are now in clinical trials or are being used as drugs. Recent advances in selection technologies and a more thorough exploration of how to deliver nucleic acids to target cells and tissues should further speed the process of drug development.
Entire article is available to purchase.